Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Profiting from a startup concept is achievable. Discover effective strategies that can help you unlock the potential of your ideas.
10,076 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AMD posted a blowout Q1 FY2026 with record revenue and booming data-center sales. The company guides stronger-than-ex...
A clear, investor-friendly breakdown of Primoris' Q1 2026 earnings. Learn what drove results, how to read backlog and...
MIAX is shaping 2026 in a dynamic way, and the first-quarter earnings transcript offers clues about growth drivers an...
Bold moves in the logistics space are reshaping Amazon’s growth story. This article breaks down what the latest annou...
Stocks all-time highs still attract buyers as earnings momentum and AI-driven demand support another leg up. Here's t...
Arthur Hayes, BitMEX co-founder and Maelstrom CIO, projects Bitcoin hitting $125K by year-end as liquidity returns. T...
Ferrari delivered a quarter that topped estimates, yet the stock moved lower. This piece deciphers what drove the bea...
XRP trades near key resistance as bets on the CLARITY Act shift. A May 14 committee vote could reshape price paths, w...
Quantum computing stocks IonQ and D-Wave have drawn big attention after a steep rally. This guide breaks down what ha...
A veteran wealth manager makes a bold move into defense stocks as geopolitical tensions rise. Learn the strategy, ris...
Bitcoin nudges toward the 85K mark as institutional flows restart and inflation data stirs volatility. The bitcoin (b...